Study identifier:BY9010/M1-403
ClinicalTrials.gov identifier:NCT00163514
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age
Perennial Allergic Rhinitis
Phase 3
No
Ciclesonide
All
636
Interventional
6 Years - 11 Years
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
Location
Location
Ste-Foy PQ, Canada, G1V 4M6
Location
Montreal, QC, Canada, H3T 1C5
Location
Ottawa, ON, Canada, K1S 0G8
Location
Ottawa, Canada, K1Y 4G2
Location
Kanata, ON, Canada, K2L 3C8
Location
Oshawa, ON, Canada, L1H1B9
Location
Niagara Falls, Canada, L2G 1J4
Location
Mississauga, Canada, L5B 1N1
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.